Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLASST-1: Neoadjuvant Nivolumab + GC in MIBC
NCT03294304Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2018
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in muscle-invasive bladder cancer (MIBC), sponsored by Masonic Cancer Center. Primary endpoint: Pathologic Response Rate. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03294304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03294304.